Liver Transplantation for Intrahepatic Cholangiocarcinoma After Chemotherapy and Radioembolization: An Intention-To-Treat Study.

IF 2.7 3区 医学 Q1 SURGERY
Transplant International Pub Date : 2024-10-31 eCollection Date: 2024-01-01 DOI:10.3389/ti.2024.13641
Marianna Maspero, Carlo Sposito, Marco A Bongini, Tommaso Cascella, Maria Flores, Marco Maccauro, Carlo Chiesa, Monica Niger, Filippo Pietrantonio, Giuseppe Leoncini, Valentina Bellia, Sherrie Bhoori, Vincenzo Mazzaferro
{"title":"Liver Transplantation for Intrahepatic Cholangiocarcinoma After Chemotherapy and Radioembolization: An Intention-To-Treat Study.","authors":"Marianna Maspero, Carlo Sposito, Marco A Bongini, Tommaso Cascella, Maria Flores, Marco Maccauro, Carlo Chiesa, Monica Niger, Filippo Pietrantonio, Giuseppe Leoncini, Valentina Bellia, Sherrie Bhoori, Vincenzo Mazzaferro","doi":"10.3389/ti.2024.13641","DOIUrl":null,"url":null,"abstract":"<p><p>Liver transplantation (LT) is a potentially curative experimental treatment for unresectable intrahepatic cholangiocarcinoma (iCC). Pre-transplant downstaging may help defining tumor aggressiveness and drive patient selection. We report the preliminary results of LT for liver-limited unresectable iCC after sequential downstaging with systemic chemotherapy and radioembolization (SYS-TARE). In case of sustained disease stability after SYS-TARE, patients underwent surgical nodal sampling and, if negative, were listed for LT. In this study, 13 patients with unresectable iCC underwent downstaging with SYS-TARE. The median age was 70 years and 77% were female. All had single bulky lesions at diagnosis. After SYS-TARE, 9 (69%) dropped out: 3 due to progressive disease after TARE with no response to second-line, 4 due to extrahepatic disease development and 2 due to positive nodal disease at pre-listing abdominal exploration. The median OS after dropout was 11.5 months. Four (31%) were successfully listed and transplanted. At pathology, viable tumor ranged from 30% to less than 5%. All four patients are alive and disease-free at 73, 40, 12, and 8 months from LT. LT for unresectable iCC after downstaging with SYS-TARE appears to select suitable patients for LT, achieving optimal oncological outcomes in case of response to therapy and no lymphnodal spread.</p>","PeriodicalId":23343,"journal":{"name":"Transplant International","volume":"37 ","pages":"13641"},"PeriodicalIF":2.7000,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11560448/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Transplant International","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/ti.2024.13641","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"SURGERY","Score":null,"Total":0}
引用次数: 0

Abstract

Liver transplantation (LT) is a potentially curative experimental treatment for unresectable intrahepatic cholangiocarcinoma (iCC). Pre-transplant downstaging may help defining tumor aggressiveness and drive patient selection. We report the preliminary results of LT for liver-limited unresectable iCC after sequential downstaging with systemic chemotherapy and radioembolization (SYS-TARE). In case of sustained disease stability after SYS-TARE, patients underwent surgical nodal sampling and, if negative, were listed for LT. In this study, 13 patients with unresectable iCC underwent downstaging with SYS-TARE. The median age was 70 years and 77% were female. All had single bulky lesions at diagnosis. After SYS-TARE, 9 (69%) dropped out: 3 due to progressive disease after TARE with no response to second-line, 4 due to extrahepatic disease development and 2 due to positive nodal disease at pre-listing abdominal exploration. The median OS after dropout was 11.5 months. Four (31%) were successfully listed and transplanted. At pathology, viable tumor ranged from 30% to less than 5%. All four patients are alive and disease-free at 73, 40, 12, and 8 months from LT. LT for unresectable iCC after downstaging with SYS-TARE appears to select suitable patients for LT, achieving optimal oncological outcomes in case of response to therapy and no lymphnodal spread.

化疗和放射栓塞后肝内胆管癌的肝移植:意向治疗研究
肝移植(LT)是治疗不可切除的肝内胆管癌(iCC)的一种潜在治愈性实验疗法。移植前的降期有助于确定肿瘤的侵袭性和选择患者。我们报告了通过全身化疗和放射栓塞(SYS-TARE)进行序贯降期后对肝局限性不可切除的iCC进行LT治疗的初步结果。如果SYS-TARE后病情持续稳定,患者将接受手术结节取样,如果结果为阴性,则列入LT治疗名单。在这项研究中,13 名无法切除的 iCC 患者接受了 SYS-TARE 的分期手术。中位年龄为 70 岁,77% 为女性。所有患者在确诊时均为单发巨大病灶。SYS-TARE后,9名患者(69%)退出:其中 3 人是由于 TARE 后病情进展且对二线治疗无反应,4 人是由于肝外疾病发展,2 人是由于上市前腹部探查时结节阳性。退出后的中位生存期为 11.5 个月。4例(31%)患者成功上市并进行了移植。病理结果显示,存活肿瘤从30%到不足5%不等。所有四名患者在LT术后分别存活73个月、40个月、12个月和8个月,且均无疾病。用SYS-TARE降期后对无法切除的iCC进行LT治疗,似乎可以选择合适的患者进行LT治疗,在对治疗有反应且无淋巴结扩散的情况下取得最佳的肿瘤治疗效果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Transplant International
Transplant International 医学-外科
CiteScore
4.70
自引率
6.50%
发文量
211
审稿时长
3-8 weeks
期刊介绍: The aim of the journal is to serve as a forum for the exchange of scientific information in the form of original and high quality papers in the field of transplantation. Clinical and experimental studies, as well as editorials, letters to the editors, and, occasionally, reviews on the biology, physiology, and immunology of transplantation of tissues and organs, are published. Publishing time for the latter is approximately six months, provided major revisions are not needed. The journal is published in yearly volumes, each volume containing twelve issues. Papers submitted to the journal are subject to peer review.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信